Corporate Governance

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Articles of association

Egetis Therapeutics AB (publ)

§ 1 Name
The company’s name is Egetis Therapeutics AB (publ).

§ 2 Registered office
The company’s registered office shall be situated in the municipality of Stockholm.

§ 3 Object of the company’s business
The object of the company’s business is to conduct research, development, manufacturing and sales of pharmaceutical products and other activities compatible therewith.

§ 4 Share capital
The share capital shall be not less than SEK 5 000 000 and not more than SEK 20 000 000.

§ 5 Number of shares
The number of shares shall not be less than 95 000 000 and not more than 380 000 000.

§ 6 Board of directors and auditors
The board of director shall consist of not less than three (3) and not more than nine (9) members.
The company shall have not less that one (1) and not more than two (2) auditors with or without deputy auditors or a registered public accounting firm.

§ 7 Notice of shareholders’ meeting
Notice to attend shareholders’ meetings shall be made through advertisements in the Swedish Official Gazette (SW: Post- och Inrikes Tidningar) and on the Company’s website. The fact that a notice to attend a meeting has been issued shall be advertised in the Swedish daily newspaper Svenska Dagbladet. If the publishing of Svenska Dagbladet would cease, announcement shall instead be made in an advertisement in Dagens Nyheter.

§ 8 Shareholders right to participate in the shareholders’ meeting
Shareholders who wish to participate in the shareholders’ meeting, must be listed in printouts or other representation of the entire share register concerning the circumstances five weekdays before the meeting, and must notify the company not later than 12:00 the day set forth in the notice of the meeting. The last-mentioned day must not be a Sunday, other public holiday, a Saturday, Midsummer Eve, Christmas Eve or New Year’s Eve and not fall earlier than the fifth weekday before the meeting.

§ 9 The shareholders’ meeting
Shareholders’ meeting shall be held not later than six months from the end of the fiscal year.

The following matters shall be addressed at the shareholders’ meeting:
1) Election of a chairman for the meeting;
2) Preparation and approval of the voting list;
3) Approval of the agenda;
4) Election of one or two persons who shall approve the minutes of the meeting;
5) Determination of whether the meeting has been duly convened;
6) Presentation of the submitted annual report and the auditors’ report and, where applicable, the consolidated financial statements and the auditors’ report for the group.
7) Resolutions regarding:
a. the adoption of the income statement and the balance sheet and, where applicable, the consolidated income statement and the consolidated balance sheet,
b. allocation of the company’s profits or losses in accordance with the adopted balance sheet,
c. discharge of the members of the board and the managing director from liability.
8) Determination of fees for members of the board of directors and, where applicable, auditors.
9) Election of board members and, where applicable, accounting firm or auditors and prospective deputy auditors.
10) Other matters as set out in the Swedish Companies Act (2005:551) or in the company’s articles of association.

§ 10 Record company
The company’s shares shall be registered in a securities register pursuant to the Swedish Financial Instruments Accounts Act (1998:1479).§ 11 Financial year
The company’s financial year comprise 1 January – 31 December.

Adopted at the Extra General Meeting on December 11, 2020.




Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10